Project Grant R21CA318124
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $217K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $657,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a multiscale approach to controlling cellular interactions in premalignant tissues. The project aims to use physical science methods to manipulate interactions between multiple cell types in precancerous tissues to restore normal tissue function. The recipient will...
- The National Cancer Institute awarded Oregon Health & Science University $1.312 million on July 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a patient-derived intestinal organoid system modeling gastrointestinal toxicity associated with immune checkpoint inhibitors used in cancer treatment. The funded work will develop air-liquid interface organoid cultures preserving epithelial and immune components from human colon mucosa to model immune-related adverse...
- The National Institutes of Health National Cancer Institute awarded Providence Health & Services - Oregon $437,113 on June 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the origin and plasticity of tumor-reactive regulatory T cells in patients with mismatch repair proficient colon cancer. The research uses single-cell RNA sequencing, single-cell T cell receptor sequencing, and totalseq analysis to characterize regulatory T cells (Tregs) and conventional...
- The National Cancer Institute awarded Oregon Health & Science University $638,532 on July 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on antigen immunodominance in regulation of anti-tumor CD8 T cell immunity and immunotherapy response. The research establishes antigen immunodominance as a novel therapeutic axis for predicting, modulating, and exploiting CD8 T cell responses to cancer. Cancer immunotherapies that activate CD8 T cells show promise...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Providence Health & Services – Oregon $1,431,420 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct spatiotemporal molecular elucidation of radiation-induced tumor microenvironment remodeling to enhance immunotherapy in head and neck cancer. The award funds research into neoadjuvant immunoradiotherapy combining checkpoint inhibition with hypofractionated...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Institute of Biomedical Imaging and Bioengineering awarded Oregon Health & Science University $195,000 on August 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop engineered tissue models that illuminate cellular crosstalk required for early tumor development, specifically focusing on the transition from pancreatic ductal adenocarcinoma precursor lesions to invasive cancer. The project...
- The National Institutes of Health National Cancer Institute awarded Cedars-Sinai Medical Center $679,353 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the protective role of PYDC5 in colorectal cancer prevention and progression. The research elucidates how PYDC5, a protein expressed in intestinal macrophages, functions as an inhibitor of the AIM2 inflammasome and shapes the tumor immune microenvironment. Preliminary findings show that PYDC5 expression...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- The National Cancer Institute awarded Health Research, Inc. (Roswell Park Division), doing business as Health Research At Roswell Park, $446,112 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct enhanced targeted therapy research for colorectal cancer. The research tests the synergistic potential of combining MAPK kinase cascade inhibitors with ribavirin, a GTP synthesis inhibitor, against BRAF- and RAS-mutated colorectal cancer. Work includes testing...